No Data
No Data
Pyxis Oncology Initiates New Combination Trial For PYX-201 And Expands Monotherapy Cohorts
Express News | Pyxis Oncology Initiates New Pyx-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $8
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $5
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move